Live from the NIH registry
Studies recruiting near Norwich right now
Top 25 of 122 recruiting studies, sorted by proximity — each links to its official registry page
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Lymphoma, Non-Hodgkin, Multiple Myeloma
Phase 2
Interventional 4,200 participants sought
William W. Backus Hospital — Norwich, Connecticut (1.9 mi)
· Sponsor: American Society of Clinical Oncology
A Novel Program Using Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia
Hemiplegia, Cerebral Palsy
N/A
Interventional 30 participants sought
Physical Therapy Program, Department of Kinesiology, University of Connecticut — Storrs, Connecticut (19.7 mi)
· Sponsor: University of Connecticut
Investigation of Egg Intake and the Relationship Between Gut Microbiome, Metabolic, and Immune Profiles
Obesity (BMI Equal to or >30), Immune Function
N/A
Interventional 78 participants sought
University of Connecticut — Storrs, Connecticut (19.7 mi)
· Sponsor: University of Connecticut
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Retroperitoneal Sarcoma, Liposarcoma
Phase 3
Interventional 250 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Radiation Retinopathy, Visual Impairment
Phase 3
Interventional 600 participants sought
Retina Consultants — Manchester, Connecticut (27.3 mi)
· Sponsor: Jaeb Center for Health Research
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma
Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8
Phase 2
Interventional 108 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: National Cancer Institute (NCI)
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Age-related Wet Macular Degeneration
Phase 1
Interventional 45 participants sought
CBCC Global Research Site:005 — Manchester, Connecticut (27.3 mi)
· Sponsor: Caregen Co. Ltd.
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
Phase 3
Interventional 3,960 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: NRG Oncology
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Phase 2, Phase 3
Interventional 992 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: National Cancer Institute (NCI)
HIV Treatment Adherence Dose Determination Trial
HIV Infections
N/A
Interventional 400 participants sought
University of Connecticut — Storrs, Connecticut (19.7 mi)
· Sponsor: University of Connecticut
Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
Resectable Intrahepatic Cholangiocarcinoma
Phase 2
Interventional 27 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: National Cancer Institute (NCI)
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Diabetic Macular Edema
Phase 1, Phase 2
Interventional 49 participants sought
Retina Group of New England, PC — Waterford, Connecticut (14.6 mi)
· Sponsor: Boehringer Ingelheim
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Neovascular Age-Related Macular Degeneration
Phase 3
Interventional 1,000 participants sought
Retina Group of New England — Waterford, Connecticut (14.6 mi)
· Sponsor: Hoffmann-La Roche
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 306 participants sought
Hartford HealthCare - Manchester — Manchester, Connecticut (27.3 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Phase 2
Interventional 360 participants sought
Seaport Investigator Site — Cromwell, Connecticut (29.0 mi)
· Sponsor: Seaport Therapeutics
The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study
Chemotherapy Induced Peripheral Neuropathy (CIPN)
N/A
Interventional 142 participants sought
Eastern Connecticut Hematology Oncology — Norwich, Connecticut (1.9 mi)
· Sponsor: Luminate Medical, Inc.
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: SWOG Cancer Research Network
Change 4 Better (C4B)
Problem Gambling
N/A
Interventional 128 participants sought
United Community & Family Services — Norwich, Connecticut (1.9 mi)
· Sponsor: Yale University
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (CRC)
Phase 3
Interventional 600 participants sought
Clinical Study Site — Norwich, Connecticut (1.9 mi)
· Sponsor: Summit Therapeutics
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Macular Degeneration, Age-Related Macular Degeneration
Phase 2, Phase 3
Interventional 960 participants sought
Retina Group of New England — Waterford, Connecticut (14.6 mi)
· Sponsor: EyeBiotech Ltd.
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: National Cancer Institute (NCI)
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Refractory Differentiated Thyroid Gland Carcinoma
Phase 3
Interventional 264 participants sought
Smilow Cancer Hospital Care Center - Waterford — Waterford, Connecticut (14.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Phase 3
Interventional 975 participants sought
Retina Group of New England — Waterford, Connecticut (14.6 mi)
· Sponsor: Regeneron Pharmaceuticals
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 630 participants sought
Eastern Connecticut Hematology and Oncology — Norwich, Connecticut (1.9 mi)
· Sponsor: BeOne Medicines
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Phase 2
Interventional 200 participants sought
Oruka Therapeutics Investigative Site — Cromwell, Connecticut (29.0 mi)
· Sponsor: Oruka Therapeutics, Inc.